Welcome to our dedicated page for Syndax Pharmaceuticals SEC filings (Ticker: SNDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the science is hard enough—decoding the disclosures behind it can feel impossible. Syndax Pharmaceuticals’ 10-K often buries trial outcomes for revumenib and axatilimab deep inside 200-plus pages, while surprise 8-K updates surface new royalty deals overnight. If you have ever asked, “Where can I find the Syndax Pharmaceuticals quarterly earnings report 10-Q filing?” or searched for “Syndax Pharmaceuticals insider trading Form 4 transactions,” you already know the challenge.
Stock Titan turns that problem into a two-minute read. Our AI-powered summaries translate technical oncology language into plain English, flagging the exact tables that spell out cash runway, R&D spend, and upcoming FDA milestones. Need the “Syndax Pharmaceuticals annual report 10-K simplified” or a quick “Syndax Pharmaceuticals earnings report filing analysis”? Get both, side-by-side with management commentary, without sifting through footnotes. Real-time alerts push every “Syndax Pharmaceuticals Form 4 insider transactions real-time,” so you can monitor executive stock transactions before the market reacts. We also map each “Syndax Pharmaceuticals proxy statement executive compensation” item to performance targets and surface every “Syndax Pharmaceuticals 8-K material events explained” entry within minutes of hitting EDGAR.
From pipeline-critical 10-Q updates to sudden 8-K clinical data releases, every filing is cataloged, timestamped, and linked to context. Investors use our platform to compare quarter-over-quarter R&D trends, track insider buying patterns, and understand collaboration economics—without drowning in jargon. Start understanding Syndax Pharmaceuticals SEC documents with AI and make faster, evidence-based decisions.
Syndax Pharmaceuticals Schedule 13G/A shows that Point72-related entities and Steven A. Cohen report shared beneficial ownership of 2,307,824 shares of Syndax common stock, representing 2.7% of the class as of the close of business on June 30, 2025. The filing states Point72 Asset Management exercises shared voting and dispositive power over these shares on behalf of an investment fund it manages; Point72 Capital Advisors is the general partner and Mr. Cohen controls both entities. The filing clarifies the position is not intended to indicate an attempt to influence control of the issuer.
Form 144 notice for SNDX reports a proposed sale of 43,200 shares of common stock through Morgan Stanley Smith Barney LLC on 08/14/2025, with an aggregate market value of $581,040.00. The shares were acquired the same day by exercise of stock options and paid for in cash. The filing lists 86,141,862 shares outstanding, and there are no reported sales by the same person in the prior three months.
The notice confirms the seller represents they have no undisclosed material adverse information and follows Rule 144 procedures for the proposed sale.
Schedule 13G/A filed for Syndax Pharmaceuticals, Inc. reports that The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly hold 5,581,828.06 shares of Syndax common stock, representing 6.5% of the class as reported for the event date 06/30/2025. The filing shows no sole voting or dispositive power and substantial shared voting power (5,581,718.06) and shared dispositive power (5,581,828.06). The cover exhibits include a joint filing agreement and identification of Goldman Sachs & Co. LLC as a subsidiary of GS Group. The registrants certify the securities are held in the ordinary course of business and not for the purpose of changing control.
Syndax Pharmaceuticals (SNDX) – Form 4 insider activity: Chief Financial Officer Keith A. Goldan purchased 1,226 common shares on 07/31/2025 under the company’s Employee Stock Purchase Plan (ESPP) at an average price of $8.43 per share. The transaction is coded “J,” confirming it is part of a tax-qualified plan rather than an open-market buy.
Following the purchase, Goldan’s direct ownership rises to 93,676 shares. No derivative securities were reported. The filing was submitted on 08/07/2025 and signed by attorney-in-fact Michael A. Metzger.
The acquisition is modest in dollar terms (≈$10 k) but represents incremental insider buying, which can be interpreted as a signal of management confidence. However, the size relative to Goldan’s total stake and SNDX’s share count suggests limited market impact.
FAQ
What is the current stock price of Syndax Pharmaceuticals (SNDX)?
What is the market cap of Syndax Pharmaceuticals (SNDX)?
